Vedanta Biosciences is touting positive new Phase 2 results for a microbe-based treatment for C. difficile, the fourth major biotech to take this approach toward the life-threatening bacterial ...

At the Canadian facility, between Nov. 19, 2013, and March 7, 2015, admitted patients were screened for C. diff toxin B gene with polymerase chain reaction on a rectal swab.

It was an award that recognized a few years and many hours of work by the staff at The Jewish Hospital. In 2009, the hospital’s C. diff incidence rate was 25.27 per 10,000 patient days.

C. difficile, an anaerobic gram-positive rod, is the most frequently identified cause of antibiotic-associated diarrhea (AAD). It accounts for approximately 15–25% of all episodes of AAD. Credit ...